Gene Therapy
Authors:
Open Access
- 14 March 2017
- book chapter
- Published by Springer Nature
- Vol. 165, 351-399
Abstract
Gene therapy refers to a rapidly growing field of medicine in which genes are introduced into the body to treat or prevent diseases. Although a variety of methods can be used to deliver the genetic materials into the target cells and tissues, modified viral vectors represent one of the more common delivery routes because of its transduction efficiency for therapeutic genes. Since the introduction of gene therapy concept in the 1970s, the field has advanced considerably with notable clinical successes being demonstrated in many clinical indications in which no standard treatment options are currently available. It is anticipated that the clinical success the field observed in recent years can drive requirements for more scalable, robust, cost effective, and regulatory-compliant manufacturing processes. This review provides a brief overview of the current manufacturing technologies for viral vectors production, drawing attention to the common upstream and downstream production process platform that is applicable across various classes of viral vectors and their unique manufacturing challenges as compared to other biologics. In addition, a case study of an industry-scale cGMP production of an AAV-based gene therapy product performed at 2,000 L-scale is presented. The experience and lessons learned from this largest viral gene therapy vector production run conducted to date as discussed and highlighted in this review should contribute to future development of commercial viable scalable processes for vial gene therapies.Keywords
This publication has 111 references indexed in Scilit:
- Efficient Large Volume Lentiviral Vector Production Using Flow ElectroporationHuman Gene Therapy, 2012
- Reproducible High Yields of Recombinant Adeno-Associated Virus Produced Using Invertebrate Cells in 0.02- to 200-Liter CulturesHuman Gene Therapy, 2011
- A Versatile Adeno-Associated Virus Vector Producer Cell Line Method for Scalable Vector Production of Different SerotypesHuman Gene Therapy, 2011
- Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard MaterialHuman Gene Therapy, 2010
- Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus ManufacturingHuman Gene Therapy, 2010
- A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High-titer rAAV Stocks From Insect CellsMolecular Therapy, 2009
- Large-Scale Adeno-Associated Viral Vector Production Using a Herpesvirus-Based System Enables Manufacturing for Clinical StudiesHuman Gene Therapy, 2009
- Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell TherapyJournal of Immunotherapy, 2009
- Identification of Host Proteins Associated with Retroviral Vector Particles by Proteomic Analysis of Highly Purified Vector PreparationsJournal of Virology, 2008
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003